Jason Zemansky
Stock Analyst at B of A Securities
(4.88)
# 53
Out of 5,152 analysts
52
Total ratings
77.78%
Success rate
46.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics | Initiates: Buy | $34 | $14.50 | +134.48% | 1 | Mar 2, 2026 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $6 | $1.87 | +220.86% | 1 | Jan 21, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $18 → $19 | $11.09 | +71.40% | 3 | Nov 28, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $17 → $26 | $21.73 | +19.65% | 6 | Nov 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $10 → $8 | $4.40 | +81.82% | 5 | Nov 18, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $8 → $7 | $0.60 | +1,071.55% | 6 | Nov 18, 2025 | |
| INSM Insmed | Maintains: Buy | $142 → $187 | $142.94 | +30.82% | 11 | Oct 27, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $60.50 | -7.44% | 5 | Oct 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $26.68 | +16.19% | 4 | Apr 1, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $8.65 | +235.26% | 2 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $31 | $21.48 | +44.32% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $2.9 → $2.5 | $2.66 | -6.02% | 5 | Jun 20, 2024 |
Eikon Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $34
Current: $14.50
Upside: +134.48%
Inhibikase Therapeutics
Jan 21, 2026
Initiates: Buy
Price Target: $6
Current: $1.87
Upside: +220.86%
Keros Therapeutics
Nov 28, 2025
Maintains: Neutral
Price Target: $18 → $19
Current: $11.09
Upside: +71.40%
Arcus Biosciences
Nov 28, 2025
Maintains: Neutral
Price Target: $17 → $26
Current: $21.73
Upside: +19.65%
Rocket Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.40
Upside: +81.82%
Werewolf Therapeutics
Nov 18, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $0.60
Upside: +1,071.55%
Insmed
Oct 27, 2025
Maintains: Buy
Price Target: $142 → $187
Current: $142.94
Upside: +30.82%
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $60.50
Upside: -7.44%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $26.68
Upside: +16.19%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $8.65
Upside: +235.26%
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $21.48
Upside: +44.32%
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $2.66
Upside: -6.02%